scholarly journals Clinical practice guidelines and consensus for the screening of breast cancer: A systematic appraisal of their quality and reporting

2021 ◽  
Author(s):  
Marta Maes‐Carballo ◽  
Luciano Mignini ◽  
Manuel Martín‐Díaz ◽  
Aurora Bueno‐Cavanillas ◽  
Khalid Saeed Khan
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Systematic Appraisal

Surgeons' opinions about the NHMRC clinical practice guidelines for the management of early breast cancer

1998 ◽  
Vol 169 (6) ◽  
pp. 300-305 ◽  
Author(s):  
Sue E Carrick ◽  
Sally Redman ◽  
Fleur Webster ◽  
Billie Bonevski ◽  
Rob W Sanson‐Fisher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Early Breast Cancer ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines

scholarly journals Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology

2018 ◽  
Vol 16 (11) ◽  
pp. 1362-1389 ◽  
Author(s):  
Therese B. Bevers ◽  
Mark Helvie ◽  
Ermelinda Bonaccio ◽  
Kristine E. Calhoun ◽  
Mary B. Daly ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Screening And Diagnosis

1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.

1998 ◽  
Vol 16 (2) ◽  
pp. 793-795 ◽  
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Clinical Practice ◽  
Clinical Oncology ◽  
Tumor Markers ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Disease Free Survival ◽  
Research Committee ◽  
American Society

OBJECTIVE The primary objective was to update the 1996 clinical practice guidelines for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast and colorectal cancers. These guidelines are intended for use in the care of patients outside of clinical trials. OPTIONS Six tumor markers for colorectal cancer and eight for breast cancer were considered. They could be recommended or not for routine use or for special circumstances. In addition to carcinoembryonic antigen (CEA) and cancer antigen (CA) 15-3, CA 27.29 also was considered in regard to circulatory tumor markers for breast cancer. OUTCOMES In general, the significant health outcomes identified for use in making clinical practice guidelines (overall survival, disease-free survival, quality of life, lesser toxicity, and cost effectiveness) were used. EVIDENCE A computerized literature search from 1994 to July 1997 was performed. VALUES The same values for Use, Utility, and Levels of Evidence were used by the Committee. BENEFITS, HARMS, AND COSTS The same benefit, harms, and costs were used. RECOMMENDATION No changes in any guidelines were recommended (see text). VALIDATION External review by the American Society of Clinical Oncology (ASCO) Health Services Research Committee and by ASCO Board of Directors. SPONSOR American Society of Clinical Oncology.

Sign in / Sign up

Export Citation Format

Share Document